Chinese General Practice ›› 2019, Vol. 22 ›› Issue (17): 2099-2105.DOI: 10.12114/j.issn.1007-9572.2019.00.041
• Monographic Research • Previous Articles Next Articles
Published:
2019-06-15
Online:
2019-06-15
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2019.00.041
[1]SIEGEL R L,MILLER K D,JEMAL A,et al.Cancer statistics[J].CA Cancer J Clin,2017,67(1):7-30.DOI:10.3322/caac.21387. [2]MALVEZZI M,CARIOLI G,BERTUCCIO P,et al.European cancer mortality predictions for the year 2016 with focus on leukaemias[J].Ann Oncol,2016,27(4):725-731.DOI:10.1093/annonc/mdw022. [3]黄志煜,李晖,范云.抗PD-1/PD-L1单抗治疗肺癌临床研究进展[J].中国肺癌杂志,2015,18(11):706-713.DOI:10.3779/j.issn.1009-3419.2015.11.09. HUANG Z Y,LI H,FAN Y.Clinical research progress of anti PD-1/PD-L1 monoclonal antibody in the treatment of lung cancer[J].Chinese Journal of Lung Cancer,2015,18(11):706-713.DOI:10.3779/j.issn.1009-3419.2015.11.09. [4]曾玉兰,刘洋洋,梁金燕,等.免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J].实用肿瘤学杂志,2017,31(4):353-358.DOI:10.11904/j.issn.1002-3070.2017.04.012. ZENG Y L,LIU Y Y,LIANG J Y,et al.Advances in drug resistance mechanism of immunological checkpoint inhibitors and post-drug resistant therapeutic strategy[J].Practical Oncology Journal,2017,31(4):353-358.DOI:10.11904/j.issn.1002-3070.2017.04.012. [5]GETTINGER S,HORN L,JACKMAN D,et al.Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer:results from the CA209-003 study[J].J Clin Oncol,2018,36(17):1675-1684.DOI:10.1200/JCO.2017.77.0412. [6]CRITTENDEN M R,ZEBERTAVAGE L,KRAMER G,et al.Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity[J].Sci Rep,2018,8(1):7012.DOI:10.1038/s41598-018-25482-w. [7]WEHLER T,THOMAS M,SCHUMANN C,et al.A randomized,phase 2 evaluation of the CHK1 inhibitor,LY2603618,administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer[J].Lung Cancer,2017,108:212-216.DOI:10.1016/j.lungcan.2017.03.001. [8]TABCHI S,KOURIE H R,KATTAN J.Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer:a new therapeutic strategy[J].Invest New Drugs,2016,34(6):794-796.DOI:10.1007/s10637-016-0383-2. [9]HELWICK C.Experts consider the new immunotherapy paradigm in advanced lung cancer[C].American:ASCO Annual Meeting,2016. [10]ARBOUR K C,MEZQUITA L,LONG N,et al.Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer[J].J Clin Oncol,2018,36(28):2872-2878.DOI:10.1200/JCO.2018.79.0006. [11]RYKEN T C,MCDERMOTT M,ROBINSON P D,et al.The role of steroids in the management of brain metastases:a systematic review and evidence-based clinical practice guideline[J].J Neurooncol,2010,96(1):103-114.DOI:10.1007/s11060-009-0057-4. [12]PAULSEN O,KLEPSTAD P,ROSLAND J H,et al.Efficacy of methylprednisolone on pain,fatigue,and appetite loss in patients with advanced cancer using opioids:a randomized,placebo-controlled,double-blind trial[J].J Clin Oncol,2014,32(29):3221-3228.DOI:10.1200/JCO.2013.54.3926. [13]YENNURAJALINGAM S,FRISBEE-HUME S,PALMER J L,et al.Reduction of cancer-related fatigue with dexamethasone:a double-blind,randomized,placebo-controlled trial in patients with advanced cancer[J].J Clin Oncol,2013,31(25):3076-3082.DOI:10.1200/JCO.2012.44.4661. [14]BEN-AHARON I,GAFTER-GVILI A,LEIBOVICI L,et al.Interventions for alleviating cancer-related dyspnea:a systematic review and meta-analysis[J].Acta Oncol,2012,51(8):996-1008.DOI:10.3109/0284186X.2012.709638. [15]LIN R J,ADELMAN R D,MEHTA S S.Dyspnea in palliative care:expanding the role of corticosteroids[J].J Palliat Med,2012,15(7):834-837.DOI:10.1089/jpm.2011.0260. [16]LIBERT C,DEJAGER L.How steroids steer T cells[J].Cell Rep,2014,7(4):938-939.DOI:10.1016/j.celrep.2014.04.041. [17]BIANCHI M,MENG C,IVASHKIV L B.Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids[J].Proc Natl Acad Sci USA,2000,97(17):9573-9578.DOI:10.1073/pnas.160099797. [18]CHEN X,MURAKAMI T,OPPENHEIM J J,et al.Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death[J].Eur J Immunol,2004,34(3):859-869.DOI:10.1002/eji.200324506. [19]CHEN X,OPPENHEIM J J,WINKLER-PICKETT R T,et al.Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE[J].Eur J Immunol,2006,36(8):2139-2149.DOI:10.1002/eji.200635873. [20]IM S J,HASHIMOTO M,GERNER M Y,et al.Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy[J].Nature,2016,537(7620):417-421.DOI:10.1038/nature19330. [21]VETIZOU M,PITT J M,DAILLERE R,et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J].Science,2015,350(6264):1079-1084.DOI:10.1126/science.aad1329. [22]SIVAN A,CORRALES L,HUBERT N,et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J].Science,2015,350(6264):1084-1089.DOI:10.1126/science.aac4255. [23]SCHELENZ S,GILES D,ABDALLAH S.Epidemiology,management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre[J].Ann Oncol,2012,23(7):1889-1893.DOI:10.1093/annonc/mdr520. [24]JERNBERG C,LOFMARK S,EDLUND C,et al.Long-term impacts of antibiotic exposure on the human intestinal microbiota[J].Microbiology,2010,156(Pt 11):3216-3223.DOI:10.1099/mic.0.040618-0. [25]LANGE K,BUERGER M,STALLMACH A,et al.Effects of antibiotics on gut microbiota[J].Dig Dis,2016,34(3):260-268.DOI:10.1159/000443360. [26]JAKOBSSON H E,JERNBERG C,ANDERSSON A F,et al.Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome[J].PLoS One,2010,5(3):e9836.DOI:10.1371/journal.pone.0009836. [27]CECILIA ARBOUR K.Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC[C].America:ASCO Annual Meeting,2018. [28]PAVLAKIS N.Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso,a study of nintedanib (N) vs.placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM)[C].America:ASCO Annual Meeting,2018. [29]DEROSA L,HELLMANN M D,SPAZIANO M,et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer[J].Ann Oncol,2018,29(6):1437-1444.DOI:10.1093/annonc/mdy103. [30]AHMED J,KUMAR A,PARIKH K,et al.Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors[J].Oncoimmunology,2018,7(11):e1507670.DOI:10.1080/2162402X.2018.1507670. [31]HUEMER F,RINNERTHALER G,WESTPHAL T,et al.Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer[J].Oncotarget,2018,9(23):16512-16520.DOI:10.18632/oncotarget.24751. [32]ARVOLD N D,LEE E Q,MEHTA M P,et al.Updates in the management of brain metastases[J].Neuro Oncol,2016,18(8):1043-1065.DOI:10.1093/neuonc/now127. [33]NAYAK L,LEE E Q,WEN P Y.Epidemiology of brain metastases[J].Curr Oncol Rep,2012,14(1):48-54.DOI:10.1007/s11912-011-0203-y. [34]KHASRAW M,POSNER J B.Neurological complications of systemic cancer[J].Lancet Neurol,2010,9(12):1214-1227.DOI:10.1016/S1474-4422(10)70220-9. [35]YANG H,LU S Q.Advances and strategy of up-to-date treatment of brain metastases[J].Biomed Research International,2010,2014(1):93-100.DOI:10.1155/2014/484161. [36]AMELOT A,TERRIER L M,MATHON B,et al.Can anticancer chemotherapy promote the progression of brain metastases?[J].Med Oncol,2018,35(3):35.DOI:10.1007/s12032-018-1097-4. [37]AKAMATSU H,KATAKAMI N,OKAMOTO I,et al.Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer:AURA3 trial[J].Cancer Sci,2018,109(6):1930-1938.DOI:10.1111/cas.13623. [38]VANSTEENKISTE J,REUNGWETWATTANA T,NAKAGAWA K,et al.CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC):data from the FLAURA study[J].Ann Oncol,2017,28(suppl 10):x7.DOI:10.1093/annonc/mdx782. [39]WEBER J S,AMIN A,MINOR D,et al.Safety and clinical activity of ipilimumab in melanoma patients with brain metastases:retrospective analysis of data from a phase 2 trial[J].Melanoma Res,2011,21(6):530-534.DOI:10.1097/CMR.0b013e32834d3d88. [40]LONG G V,ATKINSON V,LO S,et al.Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases:a multicentre randomised phase 2 study[J].Lancet Oncol,2018,19(5):672-681.DOI:10.1016/S1470-2045(18)30139-6. [41]BORDONI R,CIARDIELLO F,VON PAWEL J,et al.Patient-reported outcomes in OAK:a phase Ⅲ study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer[J].Clin Lung Cancer,2018,19(5):441-449.e4.DOI:10.1016/j.cllc.2018.05.011. [42]BARLESI F,STEINS M,HORN L,et al.Long-term outcomes with nivolumab vs docetaxel in patients with advanced NSCLC:CheckMate 017 and CheckMate 057 2-y update[C].Denmark:Esmo Congress,2016. [43]RIZVI N A,MAZIERES J,PLANCHARD D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.DOI:10.1016/S1470-2045(15)70054-9. [44]KAMATH S D,KUMTHEKAR P U.Immune checkpoint inhibitors for the treatment of entral nervous system (CNS) metastatic disease[J].Front Oncol,2018,8:414.DOI:10.3389/fonc.2018.00414. [45]GIANNONI P,BADAUT J,DARGAZANLI C,et al.The pericyte-glia interface at the blood-brain barrier[J].Clin Sci,2018,132(3):361-374.DOI:10.1042/CS20171634. [46]PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.DOI:10.1038/nrc3239. [47]BRASTIANOS P K,CARTER S L,SANTAGATA S,et al.Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets[J].Cancer Discov,2015,5(11):1164-1177.DOI:10.1158/2159-8290.CD-15-0369. [48]FIDLER I J.The biology of brain metastasis:challenges for therapy[J].Cancer J,2015,21(4):284-293.DOI:10.1097/PPO.0000000000000126. [49]HENDRIKS L.Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI)[C].America:ASCO Annual Meeting,2018. [50]DALY M E,MONJAZEB A M,KELLY K.Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer[J].J Thorac Oncol,2015,10(12):1685-1693.DOI:10.1097/JTO.0000000000000686. [51]REYNDERS K,ILLIDGE T,SIVA S,et al.The abscopal effect of local radiotherapy:using immunotherapy to make a rare event clinically relevant[J].Cancer Treat Rev,2015,41(6):503-510.DOI:10.1016/j.ctrv.2015.03.011. [52]DENG L,LIANG H,BURNETTE B,et al.Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J].J Clin Invest,2014,124(2):687-695.DOI:10.1172/JCI67313. [53]VATNER R E,COOPER B T,VANPOUILLE-BOX C,et al.Combinations of immunotherapy and radiation in cancer therapy[J].Front Oncol,2014,4:325.DOI:10.3389/fonc.2014.00325. [54]TOMASINI P,GREILLIER L,BOYER A,et al.Durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer[J].J Thorac Dis,2018,10(Suppl 9):S1032-1036.DOI:10.21037/jtd.2018.04.61. [55]KIRKPATRICK J P,KELSEY C R,PALTA M,et al.Stereotactic body radiotherapy:a critical review for nonradiation oncologists[J].Cancer,2014,120(7):942-954.DOI:10.1002/cncr.28515. [56]SCHAUE D,RATIKAN J A,IWAMOTO K S,et al.Maximizing tumor immunity with fractionated radiation[J].Int J Radiat Oncol Biol Phys,2012,83(4):1306-1310.DOI:10.1016/j.ijrobp.2011.09.049. [57]LEE Y,AUH S L,WANG Y,et al.Therapeutic effects of ablative radiation on local tumor require CD8+ T cells:changing strategies for cancer treatment[J].Blood,2009,114(3):589-595.DOI:10.1182/blood-2009-02-206870. [58]CHEN D S,MELLMAN I.Elements of cancer immunity and the cancer-immune set point[J].Nature,2017,541(7637):321-330.DOI:10.1038/nature21349. [59]LUKE J J,LEMONS J M,KARRISON T G,et al.Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors[J].J Clin Oncol,2018,36(16):1611-1618.DOI:10.1200/JCO.2017.76.2229. [60]KLUG F,PRAKASH H,HUBER P E,et al.Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy[J].Cancer Cell,2013,24(5):589-602.DOI:10.1016/j.ccr.2013.09.014. [61]DEMARIA S,FORMENTI S C.Radiation as an immunological adjuvant:current evidence on dose and fractionation[J].Front Oncol,2012,2:153.DOI:10.3389/fonc.2012.00153. [62]Cancer Genome Atlas Research Network.Comprehensive genomic characterization of squamous cell lung cancers[J].Nature,2012,489(7417):519-525.DOI:10.1038/nature11404. [63]BRAHMER J,RECKAMP K L,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.DOI:10.1056/NEJMoa1504627. [64]GAINOR J F.Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression[C].America:ASCO Annual Meeting,2018. [65]CHAMPIAT S,FERTE C,LEBEL-BINAY S,et al.Exomics and immunogenics:bridging mutational load and immune checkpoints efficacy[J].Oncoimmunology,2014,3(1):e27817.DOI:10.4161/onci.27817. [66]RIZVI N A,HELLMANN M D,SNYDER A,et al.Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J].Science,2015,348(6230):124-128.DOI:10.1126/science.aaa1348. [67]INAMURA K,YOKOUCHI Y,KOBAYASHI M,et al.WITHDRAWN:tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis[J].Lung Cancer,2016,243(1):21-28.DOI:10.1016/j.lungcan.2016.09.016. [68]LAWRENCE M S,STOJANOV P,POLAK P,et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature,2013,499(7457):214-218.DOI:10.1038/nature12213. [69]GOVINDAN R,DING L,GRIFFITH M,et al.Genomic landscape of non-small cell lung cancer in smokers and never-smokers[J].Cell,2012,150(6):1121-1134.DOI:10.1016/j.cell.2012.08.024. [70]TAKADA K,TOYOKAWA G,OKAMOTO T,et al.A comprehensive analysis of programmed cell death ligand-1 expression with the clone SP142 antibody in non-small-cell lung cancer patients[J].Clin Lung Cancer,2017,18(5):572-582.e1.DOI:10.1016/j.cllc.2017.02.004. [71]LAWRENCE M S,STOJANOV P,POLAK P,et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature,2013,499(7457):214-218.DOI:10.1038/nature12213. [72]SNYDER A,MAKAROV V,MERGHOUB T,et al.Genetic basis for clinical response to CTLA-4 blockade in melanoma[J].N Engl J Med,2014,371(23):2189-2199.DOI:10.1056/NEJMoa1406498. [73]ROONEY M S,SHUKLA S A,WU C J,et al.Molecular and genetic properties of tumors associated with local immune cytolytic activity[J].Cell,2015,160(1/2):48-61.DOI:10.1016/j.cell.2014.12.033. [74]STRICKLAND K C,HOWITT B E,SHUKLA S A,et al.Association and prognostic significance of BRCA1/2-mutation status with neoantigen load,number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer[J].Oncotarget,2016,7(12):13587-13598.DOI:10.18632/oncotarget.7277. [75]GIBBONS D L,BYERS L A,KURIE J M.Smoking,p53 mutation,and lung cancer[J].Mol Cancer Res,2014,12:3-13.DOI:10.1158/1541-7786.MCR-13-0539. [76]RIZVI H,SANCHEZ-VEGA F,LA K,et al.Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing[J].J Clin Oncol,2018,36(7):633-641.DOI:10.1200/JCO.2017.75.3384. [77]HELLMANN M D,CIULEANU T E,PLUZANSKI A,et al.Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J].N Engl J Med,2018,378(22):2093-2104.DOI:10.1056/NEJMoa1801946. [78]WU Y L,LU S,CHENG Y,et al.Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC):results of the phase 3 CheckMate 078 study[J].Cancer Res,2018,78(13):14-18.DOI:10.1158/1538-7445. |
[1] | ZHU Wenpeng, HAN Mengqi, WANG Yuxin, WANG Guoping. Trends and Projections of Incidence and Mortality of Nasopharyngeal Carcinoma in China from 1990 to 2019 [J]. Chinese General Practice, 2023, 26(34): 4269-4276. |
[2] | ZHANG Jifang, CHEN Fang, TANG Jiawen, LI Hongliang. Predictive Value of Tumor Budding and Tumor-infiltrating Lymphocytes on Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(32): 4038-4042. |
[3] | ZHANG Dongli, SHEN Chong, ZHANG Weichuan, CHEN Haibin, ZHAO Jianjun. Efficacy and Safety of Programmed Death-1/Programmed Death-1 Ligand Inhibitors in the Treatment of Renal Cell Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3815-3822. |
[4] | YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779. |
[5] | YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790. |
[6] | CHEN Lunwen, ZHOU Yang, YAN Guodong, SHEN Yi, SUN Chen, CAI Wanli, CHU Minjie, XIAO Jing. Risk of Malignant Tumor in Patients with Type 2 Diabetes: a Prospective Population-based Study [J]. Chinese General Practice, 2023, 26(26): 3238-3245. |
[7] | JI Mengying, LI Yujing, CHEN Xing, DAI Huihua, SUN Ying. Prediction Value of B-ultrasound with Tumor Markers for Malignant Transformation of Mucinous Ovarian Tumors [J]. Chinese General Practice, 2023, 26(24): 3022-3027. |
[8] | ZHANG Yushuang, KONG Lingyang, GUAN Jiachang, LI Jianbo, WANG Yiran, WANG Yu, LI Jing. 16S rDNA Sequence Analysis of the Characteristics of Gut Flora in Patients with Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(20): 2496-2502. |
[9] | ZHAO Zewei, KANG Ning, GUO Fengli, WANG Zhongyu, ZHENG Xiangqian. Effect of Aurora Kinase A Expression on Biochemical Cure in Patients after Medullary Thyroid Cancer Resection [J]. Chinese General Practice, 2023, 26(20): 2508-2512. |
[10] | DENG Yuxuan, HE Li, SONG Zhiwang, JIANG Yanxia. RET Proto-oncogene C634Y Mutation-associated Multiple Endocrine Adenomatosis Type 2A: a Case Report and Literature Review [J]. Chinese General Practice, 2023, 26(14): 1794-1798. |
[11] | SONG Pingan, CHEN Xiaoliang, YAO Yuan, GAO Jin, YANG Yang, CUI Hongchun, ZHANG Yi. Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(02): 241-247. |
[12] | Yan LI, Kunlun WANG, Hui YANG, Erjiang ZHAO, Bingxu LI, Shenglei LI, Xiaotao DONG, Ling YUAN. Prognostic Value of Lactate Dehydrogenase in Advanced Esophageal Squamous Cell Carcinoma Patients with Immunotherapy [J]. Chinese General Practice, 2022, 25(26): 3263-3269. |
[13] | Shunli LU, Jianping YU, Hongtao LI, Weikai CHEN, Andong LI, Chao CHEN, Qingyuan HE, Xiaopeng HAN. Influencing Factors of Hypoparathyroidism in Patients with Differentiated Thyroid Carcinoma after Radical Thyroidectomy [J]. Chinese General Practice, 2022, 25(23): 2869-2873. |
[14] | Jianhua XIE, Miaomiao LIU, Lili PENG, Rongsan ZHANG, Hongzhen ZHANG. Systemic Immune-inflammatory-nutritional Index and Survival in Elderly NSCLC Patients with Non-surgical Treatment [J]. Chinese General Practice, 2022, 25(17): 2082-2089. |
[15] | Gang YAO, Xinling CAO, Tao LI. Predictive Value of C-reactive Protein to Albumin Ratio for Microvascular Invasion in Single Small Hepatocellular Carcinoma [J]. Chinese General Practice, 2022, 25(12): 1429-1434. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||